Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

New study reports on Boehringer Ingelheim’s biosimilar adalimumab

by | Aug 12, 2021

A new study published in The Lancet reported that Boehringer Ingelheim’s BI 695501 (biosimilar adalimumab) has similar safety and efficacy to reference adalimumab in patients with Crohn’s disease.

Print Page
Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here

Our Latest News